[1]郑丽娜 范丽华 侯曼.可溶性ST2在STEMI患者经皮冠脉介入术后预后评估中的作用[J].心血管病学进展,2019,(5):827-831.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.040]
点击复制

可溶性ST2在STEMI患者经皮冠脉介入术后预后评估中的作用()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2019年5期
页码:
827-831
栏目:
论著
出版日期:
2019-08-25

文章信息/Info

作者:
郑丽娜 范丽华 侯曼
(解放军总医院第七医学中心门诊部,北京 100700)
关键词:

冠心病' target="_blank" rel="external"> FONT-SIZE: 10pt"> 冠心病; 经皮冠脉介入术; 可溶性ST2; 预后

Keywords:
Coronary artery disease; Percutaneous coronary intervention; Soluble ST2; Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2019.05.040
摘要:

目 的 　 评估可溶性生长刺激表达基因2蛋白（sST2） 在ST段抬高型心肌梗死（STEMI）患者经皮冠脉介入术（P CI ）后预后评估中的临床价值。 方法 　 选取201 6 年 1 月—201 9 年 1 月在解放军总医院第七医学中心行P CI 的 173 例STEMI患者，术前检测血清 sST2 ，术后随访并采集患者1年主要心血管不良事件（M ACE ）情况，采用单因素和多因素分析评估STEMI患者P CI 术前血清 sST2水平 与术后1年M ACE 之间的相关性 。 结果 　 高sST2组的1年MACE发生率（21.8%）明显高于低sST2组（10.8%）（ P =0.04）， 其中两组在心源性死亡率和非致死性心肌梗死率方面无显著差异（ P ＞0.05），而在再次血运重建率方面存在显著差异（14.9% vs 2.8%, P ＜0.01），单因素和多因素分析显示血清sST2水平是STEMI患者PCI术后MACE的独立危险因素（ HR 2.07，95% CI 1.12～5.64，P＜0.01）。结论　PCI术前血清sST2水平升高的STEMI患者，PCI术后MACEs风险增高。

Abstract:

? O bjective ? To evaluate the association ?between soluble growth stimulation expressed gene 2 (sST2) and prognosis in patients with ST-segment elevation myocardial infarction(STEMI) undergoing PCI. Methods This study enrolled 173 patients with STEMI undergoing PCI in the seventh medical center of Chinese PLA General Hospital from January 2016 to January 2019. ? Preoperative ? serum sST2 was detected for each patient ．The primary endpoints ?of 12-months’follow-up ?were ?major adverse cardiovascular events(MACE). The association between serum sST2 and 12-months ? MACE was analyzed by using univariate and multivariate analysis . Results The ? 12-months ? MACE rate of patients with high sST2 level was significant h igher than that of patients with low sST2 level(21.8% vs 10.8%, P =0.04). In details, the target vessel revascularization , ?but not cardiac death and non-fatal myocardial infarction , ?rate of patients with high sST2 level was significant higher than that of patients with low sST2 level( P <0.05). In the multiv ariate logistic regression model, serum sST2 ( H R ? 2 . 07 ,95% CI ? 1 . 12 ～ 5 . 64 , P ＜ 0.01) were also a strongly independent predictor of ?MACE . Conclusion ? ? Increased serum sST2 level is associated with the increased risk of MACE in STEMI patients undergoing PCI.

参考文献/References:

[1].3] Canfield J, Totary-Jain H. 40 Years of percutaneous coronary intervention: history and future directions[J]. J Pers Med,2018,8(4).pii:E33.
[2].[4] Younus M, Seto AH. Clinical outcomes data for instantaneous wave-free ratio-guided percutaneous coronary intervention[J]. Interv Cardiol Clin,2019,8(2):121-129.
[3].[5] Gao Y,Zhang F,Li C,et al. Optimal strategy of primary percutaneous coronary intervention for acute myocardial infarction due to unprotected left main coronary artery occlusion(OPTIMAL):study protocol for a randomised controlled trial[J]. Trials，2019,20(1):162.
[4].[6] Schmitz J,Owyang A,Oldham E,et al. IL33,an interleukin-1-like cytokine that signals
[5].via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines[J]. Immunity， 2005,23:479-490.
[6].[7] Stabler ME,Rezaee ME,Parker DM,et al. sST2 as a novel biomarker for the prediction of in-hospital mortality after coronary artery bypass grafting[J]. Biomarkers,2018,Dec 4,1-27. DOI: 10.1080/1354750X.2018.1556338. [Epub ahead of print].
[7].[8] Jenkins WS,Roger VL,Jaffe AS,et al. Prognostic value of soluble ST2 after myocardial infarction: a community perspective[J]. Am J Med,2017,130(9):1112.e9-1112.e15.
[8].[9] Xintian L,Yuanping H,Weiping H,et al. Soluble ST2 for prediction of clinical outcomes in patients
[9].with ST-segment elevation myocardial infarction receiving primary PCI[J]. Int Heart J,2019,60:19-26.
[10].[10] Puymirat E,Simon T,Steg PG,et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction[J]. JAMA,2012,308:998-1006.
[11].[11] Laukkanen JA,Kunutsor SK,Niemela M,et al. All-cause mortality and major cardiovascular outcomes comparing percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis:a metaanalysis of short-term and long-term randomised trials[J]. Open
[12].Heart,2017,4:e000638.
[13].[12] Kohli P,Bonaca MP,Kakkar R,et al.Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLINTIMI 36 trial[J]. Clin Chem,2012,58(1):257-266．
[14].[13] Weinberg EO, Shimpo M, de Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member,in cardiomyocytes and myocardial infarction[J]. Circulation,2002,106:2961-2966.
[15].[14]Shimpo M,Morrow DA,Weinberg EO,et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction[J]. Circulation,2004,109:2186-2190.
[16].[15] He L,Peng J,Zheng X,et al. Correlation study between serum soluble ST2 level and the early clinical prognosis in patients with acute ST-elevation myocardial infarction[J]. Chin Circ J,2017,32:41-45.

更新日期/Last Update: 2019-12-25